Xilio Therapeutics (XLO) Non-Current Debt (2020 - 2023)
Xilio Therapeutics (XLO) posted Non-Current Debt of $1.5 million for Q1 2023, down 51.09% sequentially from $3.2 million in Q4 2022, and down 80.68% YoY from $8.0 million in Q1 2022.
Xilio Therapeutics (XLO) Non-Current Debt (2020 - 2023) Analysis & Trends
Xilio Therapeutics has reported Non-Current Debt for 4 years, with the latest figure at $1.5 million in Q1 2023.
- Quarterly Non-Current Debt fell 80.68% year-over-year to $1.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $1.5 million (down 80.68% YoY) and the FY2022 annual result came in at $3.2 million, down 67.13% from the prior year.
- Non-Current Debt fell to $1.5 million in Q1 2023 per XLO's latest filing, from $3.2 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.6 million in Q4 2021 and troughed at $1.5 million in Q1 2023.
- A 4-year average of $6.3 million and a median of $6.9 million in 2020 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2021 and 2023: Non-Current Debt increased 29.9% in 2021, then slumped 80.68% in 2023.
- Over 4 years, Non-Current Debt stood at $7.4 million in 2020, then increased by 29.9% to $9.6 million in 2021, then plunged by 67.13% to $3.2 million in 2022, then plunged by 51.09% to $1.5 million in 2023.
- According to Business Quant data, Non-Current Debt over the past three periods registered $1.5 million, $3.2 million, and $4.8 million for Q1 2023, Q4 2022, and Q3 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 546.77 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 8.96 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.97 Mn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 1.55 Mn |
| Dec 31, 2022 | 3.17 Mn |
| Sep 30, 2022 | 4.78 Mn |
| Jun 30, 2022 | 6.39 Mn |
| Mar 31, 2022 | 8.01 Mn |
| Dec 31, 2021 | 9.63 Mn |
| Sep 30, 2021 | 9.58 Mn |
| Dec 31, 2020 | 7.41 Mn |